CVS Caremark, the pharmacy benefit manager owned by CVS Health, has restored coverage of Eli Lilly's Zepbound (tirzepatide) on its standard commercial formularies as of October 1, 2026, roughly a year and a half after dropping the drug in favor of an exclusivity arrangement with Novo Nordisk's Wegovy. The change, along with a separate addition of Lilly's oral GLP-1 pill Foundayo (orforglipron) effective June 1, 2026, was announced in a CVS Health press release on May 28, 2026.
What Actually Changed
Under the update, Zepbound returns as an additional preferred option alongside Wegovy rather than replacing it, meaning Lilly's and Novo Nordisk's flagship obesity drugs are now co-preferred on CVS Caremark's most common commercial template formularies. Foundayo's coverage change is narrower: CVS Caremark removed the "new-to-market" block that had kept the oral pill off formulary entirely, so plans that choose to cover it now can.
CVS Caremark says the changes apply to its standard commercial formularies, which it estimates cover 25 to 30 million Americans. That scale makes it one of the larger formulary shifts in the GLP-1 market this year, though it is not universal access by default.
The Catch: Coverage Still Depends on the Employer
Formulary status is not the same as guaranteed coverage. CVS Caremark's announcement is explicit that plan sponsors, meaning the employers, unions, and other organizations that actually pay for prescription benefits, retain discretion to customize their own formularies and can still exclude GLP-1 drugs for weight loss entirely, regardless of what CVS Caremark's template includes. Co-preferred status simply means that sponsors who do choose to cover GLP-1 obesity drugs now have both major brands available on equal footing, rather than being locked into one manufacturer's product.
Why CVS Made the Switch Back
CVS Caremark had moved to a Wegovy-preferred formulary structure in mid-2025 as part of a rebate arrangement with Novo Nordisk, a decision that drew visible pushback from patients and prescribers who felt tirzepatide-based drugs worked better for them individually. The reversal lands amid intensifying competition between Lilly and Novo Nordisk across the obesity drug market, including competing earnings results and dueling late-stage pipeline data throughout 2026. CVS Caremark frames the broader shift toward multiple preferred options as a affordability play, pointing to its history of double-digit year-over-year savings for template-formulary customers across the weight-management drug category.
Regulatory Status, for Context
Both drugs affected by this formulary change are FDA-approved: tirzepatide (Zepbound) is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and orforglipron (Foundayo) is an FDA-approved oral GLP-1 receptor agonist, also indicated for chronic weight management. This is a benefits and access story, not a change in either drug's approval status or safety labeling.
What This Means If You're on One of These Drugs
If you're currently on Wegovy, Zepbound, or considering Foundayo, formulary status is only one piece of what determines your out-of-pocket cost. The specific plan your employer or union selected, your deductible structure, and whether your plan opted in to weight-management coverage at all still determine what you'll actually pay. The most reliable way to find out your specific situation is to call your plan's member services line or ask your prescriber's office to run a benefits check, rather than assuming formulary news translates directly into your own coverage. As always, any decision about starting, switching, or stopping a GLP-1 medication should be made with your prescribing physician, not on the basis of insurance news alone.